Company intelligence / Profile preview

CANbridge Care Pharma Hong Kong

Suzhou, Jiangsu, China

Ownership: Private
Employees: ~67
Development stage: Other

Overview

CANbridge has three approved rare disease products: Hunterase (ERT for Hunter syndrome, launched 2021), Livmarli (IBAT inhibitor for ALGS and PFIC, launched 2024), Gaurunning (ERT for Gaucher disease, approved 2024). Pipeline includes CAN106 (anti-C5 mAb, Phase 1b/2 positive data), CAN103/104/105, and gene therapies in preclinical/early development.

Therapeutic areas: HematologyEndocrinologyRare DiseasesGastroenterology
Modalities: Enzyme replacement therapyMonoclonal antibodyBispecific antibodySmall moleculeGene therapy
Industry: Biotech

Partnerships

Mirum Pharmaceuticals (Livmarli license)GC Pharma (Gaurunning license)WuXi BiologicsBaheal Medical (commercial services)UMass Medical School (gene therapy)

Beyond the preview

Go deeper on CANbridge Care Pharma Hong Kong.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CANbridge Care Pharma Hong Kong.

Explore the full profile